Acquisition by Herskowitz Neil of 1000 shares of Avenue Therapeutics at 4.52 subject to Rule 16b-3
| ATXI Stock | USD 1.32 0.02 1.49% |
Under 62% of Avenue Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Avenue Therapeutics stock suggests that many investors are alarmed at this time. Avenue Therapeutics' investing sentiment shows overall attitude of investors towards Avenue Therapeutics.
Avenue |
Filed transaction by Avenue Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Avenue Therapeutics Fundamental Analysis
We analyze Avenue Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avenue Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avenue Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Avenue Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Avenue Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avenue Therapeutics stock to make a market-neutral strategy. Peer analysis of Avenue Therapeutics could also be used in its relative valuation, which is a method of valuing Avenue Therapeutics by comparing valuation metrics with similar companies.
Peers
Avenue Therapeutics Related Equities
| REVB | Revelation Biosciences | 5.76 | ||||
| HOTH | Hoth Therapeutics | 3.23 | ||||
| BDRX | Biodexa Pharmaceticals | 0.24 | ||||
| PALI | Palisade Bio | 4.67 | ||||
| QNRX | Quoin Pharmaceuticals | 6.45 | ||||
| WINT | Windtree Therapeutics | 7.14 | ||||
| VRAX | Virax Biolabs | 11.98 | ||||
| ALLR | Allarity Therapeutics | 16.31 |
Complementary Tools for Avenue Stock analysis
When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |